Literature DB >> 18182240

Ca2+ signalling of kinins in cells expressing rat, mouse and human B1/B2-receptor.

Radka Zubakova1, Andreas Gille, Alexander Faussner, Ulrich Hilgenfeldt.   

Abstract

With respect to functional aspects, the kallikrein-kinin-system can be divided into a plasma kallikrein-kinin-system and a tissue kallikrein-kinin-system. At least four functional kinin peptides act via two different G-protein-coupled receptors, an inducible B1-receptor and a constitutively expressed B2-receptor. B1R and B2R couple to G(q/11) and lead via phospholipase C to Ca2+ mobilization. In humans both, bradykinin and kallidin are agonists on the B2-receptor. In contrast, bradykinin is believed to be the only kinin acting on the B2R in rats and mice. However, recently we have isolated a kallidin-like-peptide from plasma and urine of rats. Until now the kinin ligand-receptor interactions were mainly characterized in binding studies. However, receptor affinity does not inevitably correspond with the intrinsic activity of an agonist. The aim of the present study was to investigate intracellular calcium mobilization to quantify mouse, rat and human B1- and B2-receptor activation by bradykinin, kallidin, des-Arg9-bradykinin, des-Arg10-kallidin, and of the two novel rat kinins, kallidin-like-peptide and des-Arg10-kallidin-like-peptide. In cells stably expressing the human, rat, and mouse B2-receptor, respectively, bradykinin, kallidin, and kallidin-like-peptide were nearly equipotent (EC50, 10(-12)M) at eliciting Ca2+-transients. Their des-Arg-derivatives were 10(3)-fold less potent. In cells expressing B1-receptor the des-Arg derivatives elicited Ca2+-signals at an EC50 in the order of 10(-9)M. Major differences between these peptides could not be observed. Bradykinin, kallidin, and kallidin-like-peptide caused a Ca2+-signal at substantially higher concentrations in the order of 10(-7)M. The data show that des-Arg9-bradykinin, des-Arg10-kallidin, and des-Arg10-kallidin-like-peptide are equipotent agonists at the B1-receptor. Bradykinin, kallidin and kallidin-like-peptide are equipotent agonists at the B2-receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18182240     DOI: 10.1016/j.intimp.2007.10.001

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  9 in total

Review 1.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

2.  Characterization of dual agonists for kinin B1 and B2 receptors and their biased activation of B2 receptors.

Authors:  Xianming Zhang; Jessica L Lowry; Viktor Brovkovych; Randal A Skidgel
Journal:  Cell Signal       Date:  2012-04-12       Impact factor: 4.315

3.  IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism.

Authors:  P P C Souza; A B Brechter; R I Reis; C A S Costa; P Lundberg; U H Lerner
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

Review 4.  The kallikrein-kinin system in health and in diseases of the kidney.

Authors:  Masao Kakoki; Oliver Smithies
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

5.  Kinin release from human kininogen by 10 aspartic proteases produced by pathogenic yeast Candida albicans.

Authors:  Andrzej Kozik; Mariusz Gogol; Oliwia Bochenska; Justyna Karkowska-Kuleta; Natalia Wolak; Wojciech Kamysz; Wataru Aoki; Mitsuyoshi Ueda; Alexander Faussner; Maria Rapala-Kozik
Journal:  BMC Microbiol       Date:  2015-03-04       Impact factor: 3.605

6.  Involvement of Bradykinin B2 Receptor in Pathological Vascularization in Oxygen-Induced Retinopathy in Mice and Rabbit Cornea.

Authors:  Erika Terzuoli; Lucia Morbidelli; Ginevra Nannelli; Antonio Giachetti; Sandra Donnini; Marina Ziche
Journal:  Int J Mol Sci       Date:  2018-01-23       Impact factor: 5.923

7.  Exogenous Pancreatic Kallikrein Improves Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetes.

Authors:  Meng Wu; Yeping Yang; Meng Wang; Fangfang Zeng; Qin Li; Wenjuan Liu; Shizhe Guo; Min He; Yi Wang; Jie Huang; Linuo Zhou; Yiming Li; Ji Hu; Wei Gong; Zhaoyun Zhang
Journal:  Front Pharmacol       Date:  2018-08-07       Impact factor: 5.810

8.  Peptidylarginine Deiminase of Porphyromonas gingivalis Modulates the Interactions between Candida albicans Biofilm and Human Plasminogen and High-Molecular-Mass Kininogen.

Authors:  Justyna Karkowska-Kuleta; Magdalena Surowiec; Mariusz Gogol; Joanna Koziel; Barbara Potempa; Jan Potempa; Andrzej Kozik; Maria Rapala-Kozik
Journal:  Int J Mol Sci       Date:  2020-04-03       Impact factor: 5.923

9.  Pharmacological suppression of the kallikrein kinin system with KVD900: An orally available plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

Authors:  Edward J Duckworth; Nivetha Murugesan; Lily Li; Louise J Rushbrooke; Daniel K Lee; Gian Marco De Donatis; Andreas Maetzel; Christopher M Yea; Sally L Hampton; Edward P Feener
Journal:  Clin Exp Allergy       Date:  2022-03-20       Impact factor: 5.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.